Developing a new treatment for immune thrombocytopenia using a specialized enzyme
Official title: Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
Funded at Cyrus Biotechnology, INC. · NIH-11069861 · Data updated 2026-11-12
This study is testing a new treatment for people with immune thrombocytopenia (ITP) that uses a specially designed enzyme to help reduce harmful antibodies and improve platelet counts, aiming to provide a safer and more effective option than what’s currently available.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cyrus Biotechnology, INC. NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | December 20, 2024 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $300,000 |
| NIH project number | 1R43AI188988-01 |
| Project ID | NIH-11069861 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with immune thrombocytopenia who have not responded adequately to existing treatments.
✕Less likely to help
Patients with other forms of thrombocytopenia not related to IgG autoantibodies may not benefit from this research.
What this research studies
This research focuses on creating a novel treatment for immune thrombocytopenia (ITP), an autoimmune disorder characterized by low platelet counts due to IgG autoantibodies. The approach involves engineering a bacterial enzyme, IdeS, to effectively deplete these harmful antibodies while minimizing side effects. By utilizing advanced protein design techniques, the researchers aim to enhance the enzyme's effectiveness and longevity in the body. Patients may benefit from a more effective and safer treatment option compared to current therapies.
Why it matters
Potential benefit: If successful, this research could provide a more effective and durable treatment option for patients suffering from immune thrombocytopenia.
How similar studies have gone: Previous research has shown promise in using similar enzymatic approaches for antibody depletion, indicating potential for success in this novel application.
Where this research is happening
-
Cyrus Biotechnology, INC.
Seattle, United States Active
Researchers
- Principal investigator: Procko, Erik — Cyrus Biotechnology, INC.
- Study coordinator: Procko, Erik
Related research
Other NIH-funded projects on the same topics.
-
Molecular mechanisms behind immune-related low platelets and clots in transfusion medicine
This grant supports a team of researchers to understand how immune factors cause low platelets and abnormal clots, with a focus on transfusion medicine and pediatric to adult patients.
-
Understanding Immune Blood Disorders Affecting Platelets
This program explores how the immune system causes low platelet counts and blood clots in people of all ages, from newborns to adults.
-
Understanding how platelet strength relates to bleeding risk in immune thrombocytopenia
This study is looking at how strong individual platelets are in people with immune thrombocytopenic purpura (ITP) to see if that can help doctors figure out who might be at a higher risk for bleeding and need treatment, so they can avoid giving unnecessary treatment to those who are less at risk.
-
Understanding how immune responses affect blood platelet levels
This study is looking into how the immune system affects low platelet counts and blood clotting issues, with the goal of finding better treatments for people of all ages, from newborns to adults.
-
Unified and fair multimodal learning for autoimmune diseases
A patient-friendly AI approach will combine many kinds of health data to improve diagnosis and personalized care for autoimmune diseases, including lupus.
-
Sub-second acetylcholine release in the brain for Alzheimer’s dementia
A small, quick stimulations-based study aims to boost a brain chemical called acetylcholine to help people with Alzheimer’s disease by using a targeted brain stimulation approach.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.